somatotroph raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
In many metabolic reactions, a protein that acts as an electron carrier binds to an enzyme that acts as its reductase. After it receives an electron, it dissociates and then binds to the next enzyme that acts as its oxidase (i.e. an acceptor of the electron). These interactions between proteins are dependent on highly specific binding between proteins to ensure efficient electron transfer. Examples: mitochondrial oxidative phosphorylation chain system components cytochrome c-reductase / cytochrome c / cytochrome c oxidase; microsomal and mitochondrial P450 systems. In the case of the mitochondrial P450 systems, the specific residues involved in the binding of the electron transfer protein adrenodoxin to its reductase were identified as two basic Arg residues on the surface of the reductase and two acidic Asp residues on the adrenodoxin. More recent work on the phylogeny of the reductase has shown that these residues involved in protein–protein interactions have been conserved throughout the evolution of this enzyme.
=== TEX86 === Because the number of cyclopentane moieties in a GDGT compound is related to the temperature of the growth environment, with increasing numbers of cyclopentane rings resulting in increased thermal stability and allowing for survival at higher temperatures, GDGT distribution and abundance can be employed as paleoclimate proxies. TEX86 is one such paleothermometer which relates distribution and relative abundance of GDGT-1, GDGT-2, GDGT-3, and crenarchaeol isomer to past sea surface temperature (SST) (see TEX86). GDGT-0, GDGT-4, and crenarchaeol are excluded from consideration for this proxy due to their very high abundances relative to isoGDGTs 1–3. The relationship between isoGDGT distribution and temperature is not linear, and some studies have demonstrated its distinctive bias towards unrealistically cold temperatures in the lower latitudes. Current research suggests TEX86 works best in the temperature range 15-34 degrees Celsius. Seasonal variability in archaeal productivity and depth in the water column at which the archaea grow should be considered prior to employing this proxy.
Pathogenic bacteria are bacteria that can cause disease. This article focuses on the bacteria that are pathogenic to humans. Most species of bacteria are harmless and many are beneficial but others can cause infectious diseases. The number of these pathogenic species in humans is estimated to be fewer than a hundred. By contrast, several thousand species are considered part of the gut flora, with a few hundred species present in each individual human's digestive tract. The body is continually exposed to many species of bacteria, including beneficial commensals, which grow on the skin and mucous membranes, and saprophytes, which grow mainly in the soil and in decaying matter. The blood and tissue fluids contain nutrients sufficient to sustain the growth of many bacteria. The body has defence mechanisms that enable it to resist microbial invasion of its tissues and give it a natural immunity or innate resistance against many microorganisms. Pathogenic bacteria are specially adapted and endowed with mechanisms for overcoming the normal body defences, and can invade parts of the body, such as the blood, where bacteria are not normally found. Some pathogens invade only the surface epithelium, skin or mucous membrane, but many travel more deeply, spreading through the tissues and disseminating by the lymphatic and blood streams.
It details potential threats stemming from misuse, malfunction, and societal disruption, with the objective of informing policy through evidence-based findings, without providing specific recommendations. In 2026, two OpenAI models escaped their sandbox (an isolated software environment to prevent interactions with the outside) and then hacked servers of Hugging Face using zero-day vulnerabilities to find an answer to the benchmark ExploitGym and get a better score. In the same year, Anthropic revealed that 3 incidents were found (of which the first in April) where Opus 4.7, Mythos 5, and an internal research test model compromised the infrastructure of three different unnamed organizations using basic techniques. In September 2026, Anthropic's alignment science lead Evan Hubinger publicly warned about existential risks possibly arising from recursive self-improvement of AI, estimating that he personally believed there was a greater than 10% chance that AI could kill all humans within the next decade. His comments followed the resignation of former Anthropic and OpenAI researcher Jacob Coxon, who criticised both companies for pursuing self-improving superintelligence without adequate safeguards. The warnings prompted calls for greater international cooperation, including a proposal by former UK Cabinet Office minister Darren Jones for a multinational treaty on the safe development of superintelligence. Later that month, Anthropic`s CEO Dario Amodei committed to granting embedded evaluators employee-level access to review new AI models.
In theory, "an allergen must have at least 2 IgE-binding epitopes, and each epitope must be at least 15 amino acid residues long, to trigger a type 1 hypersensitivity reaction." Experiments also show that this degree of hydrolysis is sufficient to not trigger IgE binding from GP19S-allergic patients. Allergenicity of eHVP depends on the specific food source and the enzyme used. Alcalase is able to render chickpea and green pea completely non-immunoreactive but papain only achieves partial reduction. Alcalase is also unable to make white beans non-reactive due to the antinutritional factors preventing complete digestion. Alcalase, but not "Flavourzyme" (a commercial Aspergillus oryzae protease blend for eHVP production), is able to make roasted peanut non-reactive.
Sources: en.wikipedia.org
Cerebrosides (monoglycosylceramides) are a group of glycosphingolipids which are important components of animal muscle and nerve cell membranes. They consist of a ceramide with a single sugar residue at the 1-hydroxyl moiety. The sugar residue can be either glucose or galactose; the two major types are therefore called glucocerebrosides (a.k.a. glucosylceramides) and galactocerebrosides (a.k.a. galactosylceramides). Galactocerebrosides are typically found in neural tissue, while glucocerebrosides are found in other tissues.
Pyruvate formate-lyase activating enzyme (PFL-AE) catalyzes the activation of PFL, a central enzyme in anaerobic glucose metabolism in microbes. Benzylsuccinate synthase (BSS) is a central enzyme in anaerobic toluene catabolism.
Hubert Humphrey, Rep. Findley's bill ultimately became Title XII of the Foreign Assistance Act, via an amendment to the FAA passed in 1975. Title XII created the Board for International Food and Agricultural Development (BIFAD), with seven members representing U.S. universities and agricultural technology institutions who advise USAID on Title XII implementation. The impact of all these actions of the early 1970s on the overall scale of U.S. development assistance is indicated by the change in the number of U.S. staff in field missions. In 1969, the year when Nixon took office, the number was already decreasing from its Vietnam War high of 8,717 and had reached 7,701. By 1976, near the end of the Nixon-Agnew and Ford-Rockefeller administrations, it was 2,007.
One aptamer, in particular, proved effective as a recognition element in an electrochemical sensor, enabling the detection of sGP and GP1.2 in solution, as well as GP1.2 within a membrane context. The results of this research point to the intriguing possibility that certain regions on protein surfaces may possess aptatropic qualities. Identifying the key features of such sites, in conjunction with improved 3-D structural predictions for aptamers, holds the potential to enhance the accuracy of predicting aptamer interaction sites on proteins. This, in turn, may help identify aptamers with a heightened likelihood of binding proteins with high affinity, as well as shed light on protein mutations that could significantly impact aptamer binding. This comprehensive understanding of the structure-based interactions between aptamers and proteins is vital for refining the computational predictability of aptamer-protein binding. Moreover, it has the potential to eventually eliminate the need for the experimental SELEX protocol.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.